Rhythm Pharmaceuticals (RYTM) Net Margin (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Net Margin data on file, last reported at 94.4% in Q1 2026.

• On a quarterly basis, Net Margin rose 6100.0% year-over-year to 94.4% in Q1 2026; TTM through Mar 2026 was 95.71%, a 3142.0% increase from a year earlier, with the FY2025 full-year figure at 106.41%, up 9691.0% from the prior year.
• Net Margin for Q1 2026 stood at 94.4%, down from 85.3% in the prior quarter.
• Over the last five years, Net Margin for RYTM reached as high as 527.99% in Q4 2022 and fell as low as 3693.79% in Q1 2022.
• Historically, Net Margin has averaged 420.6% across 5 years, with a median of 155.39% in 2025.
• On a YoY basis, Net Margin climbed as much as 1239263 bps in 2022 and fell as far as 12869379 bps in 2022.
• Year by year, Net Margin stood at 527.99% in 2022, then plunged by 133 bps to 171.8% in 2023, then surged by 38 bps to 106.7% in 2024, then increased by 20 bps to 85.3% in 2025, then declined by 11 bps to 94.4% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 94.4% in Q1 2026, 85.3% in Q4 2025, and 105.81% in Q3 2025.